A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age
Latest Information Update: 29 Mar 2023
At a glance
- Drugs Influenza virus vaccine quadrivalent-Seqirus (Primary) ; MF 59
- Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections; Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Vaccines; Seqirus
- 24 May 2020 Russia was the planned location according to European Clinical Trials Database
- 12 May 2020 Results published in the Pediatric Infectious Disease Journal
- 30 Aug 2019 According to an Seqirus, CSL Media Release, new clinical data from this study were presented at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.